NCT04190823View on ClinicalTrials.gov

A Study of RC98 in Subjects With Advanced Malignant Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

March 15, 2020

Primary Completion Date

December 28, 2023

Study Completion Date

December 30, 2023

Conditions
Solid Tumors
Interventions
DRUG

RC98

Participants will be allocated to one of the following dose groups: 0.003, 0.03, 0.3, 2.5, 5.0, 10.0, 15.0 and 20.0 mg/kg, and receive one treatment of RC98 followed by 28 days of dose limited toxicity (DLT) observation period.

Trial Locations (1)

300060

Tianjin Cancer Hospital, Tianjin

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY